checkAd
    Startseite > Aktien > Arch Biopartners > Nachrichten
    Arch Biopartners Aktie
    1,9000
     
    CAD
    -5,94 %
    -0,1200 CAD
    Letzter Kurs 26.04.24 TSX Venture
    1,9000
     
    CAD
    700 STK
    Geldkurs 26.04.24
    1,9900
     
    CAD
    5.000 STK
    Briefkurs 26.04.24
    ISIN: CA03938C1041 · WKN: A1CYFF · SYM: ARCH · Kanada

    Neueste Nachrichten

    St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
    16.04.24 · globenewswire · Arch Biopartners
    UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
    03.04.24 · globenewswire · Arch Biopartners
    Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
    02.04.24 · globenewswire · Arch Biopartners
    Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2
    18.03.24 · globenewswire · Arch Biopartners
    University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
    15.03.24 · globenewswire · Arch Biopartners
    Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
    07.03.24 · globenewswire · Arch Biopartners
    Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury
    27.02.24 · globenewswire · Arch Biopartners
    Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
    10.01.24 · globenewswire · Arch Biopartners
    Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
    03.01.24 · globenewswire · Arch Biopartners
    Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
    21.12.23 · globenewswire · Arch Biopartners
    Grant of Options to Directors and Officers
    18.12.23 · globenewswire · Arch Biopartners
    Shares for Interest Debt Settlement
    24.10.23 · globenewswire · Arch Biopartners